MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.

  • Etude concernée: IFCT-0002
  • Auteurs / Authors: Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G.
  • Journal / Conference: Oncotarget
  • Année / Year: 2016
  • PMID: 28008145
  • Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/28008145
  • PDF: MSH2_-_IFCT_00002_-_oncotarget-08-4313.pdf